An LP with industry backgrounds and direct investment capabilities

Gambol Pet Group was founded in 2006, mainly engaged in the research and development, production and sales of pet food, the main products include dog and cat staple food series, snack series and health care products series. The company always adheres to the concept of "global vision, continuous innovation" and is committed to producing nutritious and healthy pet food that consumers need.

Shanghai Chemspec Corporation was established in 1996 and is a high-tech enterprise engaged in the research and development, production, and sales of fluorinated fine chemicals. The company is known for its research and development and manufacturing of fluorine-containing specialized chemicals, which are widely recognized in the Chinese industry. Its products are globally applied in the fields of display materials, new energy battery materials, electronic chemicals, functional materials, and other special chemicals. The company is headquartered in Shanghai, China, and has established large-scale production bases in Shanghai Fengxian Chemical Industry Zone, Zhejiang Quzhou High tech Industrial Park, and Lanzhou New Area in Gansu. Kangpeng Technology not only delivers high-quality products at competitive prices in a timely manner, but also provides customers with a one-stop service from product development to commercial production.

Cutia Therapeutics was founded in 2019,  is a research and development biopharmaceutical company focused on dermatology, committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of skin disease treatment and care markets. As of now, the company has established a wide product portfolio, covering nine products and candidate products, targeting the four main areas of the broad skin disease treatment and care market, namely local fat accumulation management drugs, hair diseases and care, skin diseases and care, and epidermal anesthesia. The company is developing candidate drugs for five clinical stages and four preclinical stages. In addition, the company also distributes two commercial products developed by overseas partners.

Shanghai Southchip Semiconductor Technology Co., Ltd. is a nationally leading designer of analog and embedded chips. With a strong focus on power and battery management, the Company operates multiple product lines that include charge pumps, DC/DC converters, AC/DC converters, wired charging, wireless charging, fast charging protocols, and lithium battery protection. Southchip has launched several highly successful products that incorporate its proprietary core technologies, such as voltage boost charging, charge pumps, and GaN direct drive, which have gained widespread recognition in the industry. Additionally, the Company offers comprehensive wired and wireless fast charging solutions that cater to various power requirements, ranging from AC to batteries. The product portfolio covers the full spectrum of power grades, ranging from 10W to 240W.

Southchip’s charge pump series fast charging products have broken the monopoly held by foreign companies. These products have been embraced by renowned mobile phones and tablets, with direct supplier system certification completed. The Company’s DC/DC converters, wired charging, wireless charging, and embedded protocol products have gained widespread adoption in both consumer and pan-industrial markets. Notably, several products have met the standards of AEC-Q100 automotive quality certification, enabling them to achieve pre-assembly mass production for a diverse range of vehicle models. At present, Southchip is at the forefront of providing comprehensive solutions for in-vehicle wireless and wired charging. The Company boasts a strong R&D team, an independent quality control team, and dedicated sales and support teams that work closely with customers. This ensures high-quality development and design of products. Furthermore, Southchip has gained extensive recognition and support from both the upstream and downstream industry chains as well as capital investors. It has received capital injections from the Shanghai IC Industry Fund, China Fortune-Tech Capital, Sequoia Capital, OPPO, Xiaomi, and Vivo, which have greatly accelerated its growth trajectory. 

Driven by a commitment to product timeliness and performance, and guided by a corporate culture that values continuous exploration and innovation, Southchip is fully dedicated to providing customers with system solutions featuring high levels of performance, quality, and cost effectiveness. The Company is poised to become a global leader in the field of analog and embedded chip design.

The UniteChem Group is headquartered in the Suqian Ecological Chemical Technology Industrial Park in Jiangsu Province. As a conglomerate, UniteChem operates across multiple sectors, including chemical R&D, application R&D, production, marketing, imports and exports, and machinery manufacturing. The Group has a workforce of over 1,800 employees. In 2022, UniteChem recorded sales revenues of RMB 1.792 billion, with tax revenues exceeding RMB 156 million.

UniteChem specializes in the production of polymer additives, chemical intermediates, and chemical environmental protection equipment, with a primary focus on light stabilizers. The Group also provides plastic aging solutions and domestic and international trade services. Its products are widely used in industries such as agricultural films, plastic weaving, artificial grass, wood-plastic composites, modified plastics, and coatings. These products are exported to more than 30 countries.

Since relocating to Suqian in 2007, the Group has established a large number of subsidiaries, including Suqian UniteChem Technology, Suqian UniteChem Additives, Suqian Shengrui New Materials, Suqian Shengjin New Materials, Nanchong UniteChem New Materials, Suqian UniteChem Commerce & Trade, Shanghai Lianhong Commerce & Trade, Unitechem GmbH (Germany), Suqian Lianhong New Materials, Suqian UniteChem Technology Shanghai Branch, Suqian Xiangwang Machinery Equipment, and Nanchong Xiangwang Machinery Equipment. In March 2023, the UniteChem Group successfully listed on the Shanghai Stock Exchange.

The Group has established research facilities, testing bases, and marketing centers in Suqian, Shanghai, and Europe. Moreover, UniteChem has forged solid partnerships on R&D and application with higher-education institutions, including Fudan University, Tongji University, Shanghai University, East China University of Science and Technology, Shaanxi University of Science and Technology, Xi’an Technological University, and Beijing University of Chemical Technology. These partnerships have led to the establishment of various research institutions, such as the Engineering Technology Center for Flame Retardant and Weather Resistant Materials, the Research Center for Polymer Photostabilization Technology Engineering, and the Engineering Technology Center for Polymer Material Functionalization.

In the past two years, UniteChem has received numerous honors and accolades, including recognition as a national champion enterprise, a national “little giant” innovative enterprise, a national high-tech enterprise, a national CNAS-certified laboratory, a potential unicorn enterprise in the Jiangsu High-tech Industrial Development Zone, a “Green Enterprise” in environmental credit rating evaluations, an enterprise technology center of Jiangsu, a recipient of the May 1st Credential of Jiangsu, the Pioneer of Workers in Jiangsu, one of the first chain-leading enterprises in Suqian, and one of the top 50 industrial enterprises in the city. The Group’s achievements encompass areas such as talent education, science and technology, fire safety, environmental protection, poverty alleviation, sports and culture, Party building, and union development.

UniteChem stands as one of the world’s largest manufacturers of light stabilizers, casting a radiant glow across the global realm of plastic additives. Focusing on the production of high-quality additives and collaborating with industry peers, UniteChem is determined to gain greater recognition and appreciation by continuously enhancing its quality and reputation. Committed to quality excellence, the Group strives to create exceptional brands for the nation and contribute to the betterment of humanity.

Founded in Beijing in 2001, BMC Medical Co., Ltd. owns multiple registered trademarks, including RESmart. The Company is dedicated to providing users worldwide with comprehensive service solutions for sleep-related breathing disorders and chronic respiratory diseases.

Founded in July 2014, Zhejiang Power New Energy Co., Ltd. is a national high-tech enterprise specializing in the production, R&D, and marketing of precursor materials for lithium-ion batteries used in electric vehicles. The Company is located in Zhuji City, Zhejiang Province, covering an area of about 13.33 hectares.

Over the years, Zhejiang Power has forged close partnerships with renowned universities and research institutions, such as Central South University and CAS Institute of Process Engineering. Moreover, the Company boasts a high-caliber R&D team, which comprises more than 100 professionals, including individuals with doctoral or master’s degrees, and engineering technicians. This has enabled Zhejiang Power to establish research platforms such as the Academician Workstation, the Zhejiang Provincial Enterprise Technology Center, the Zhejiang Provincial High-tech Enterprise R&D Center, and the Metallurgical Engineering Technology Research Center for Difficult-to-Treat Nickel-Cobalt Resources in the Non-ferrous Industry. 

Zhejiang Power has proprietary preparation technologies for precursor materials, including NCM111, NCM523, NCM622, NCM811, and NCA. The Company holds over 40 patents, and its high-end products, such as large particle NCM622, single crystal NCM622, and NCM811, have gained significant recognition in the market. Notably, its single crystal low-cobalt product consistently ranks among the top in domestic sales. These products have been successfully integrated into the supply chain systems of prominent domestic and international companies, including Shanshan Energy and Xiamen Tungsten New Energy.

Biocytogen (02315.HK) is a global biotech company that drives the R&D of new drugs with innovative technologies. The Company is committed to becoming a global source of new drugs, with a mission to safeguard human health by producing a constant stream of new drugs based on technological innovation. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal antibody development, Biocytogen has integrated its bi-specific/multi-specific antibody and nanobody development platforms, animal in-vivo drug efficacy screening platforms, and strong clinical development expertise to streamline its entire drug development process. Currently, Biocytogen is undertaking a large-scale project to develop first-in-class and best-in-class antibody drugs for more than 1,000 targets, known as Project Integrum (RenMice® HiTS Platform). As of December 31, 2022, Biocytogen has signed 34 drug co-development, licensing, and transfer agreements, and has concluded RenMice® licensing deals with 17 enterprises, including several multinational companies (MNCs). Biocytogen’s core pipeline is comprised of 11 drugs under development. The Company has established project partnerships for four clinical assets out of a total of six. Going forward, Biocytogen will continue to collaborate with its global partners to deliver a wide range of antibody drugs for the benefit of patients. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu; Shanghai; Boston, US; and Heidelberg, Germany. 

Shanghai MicroPort EP MedTech Co., Ltd. (MicroPort EP) was established on August 31, 2010 in the Shanghai International Medical Park. As a high-tech enterprise, MicroPort EP specializes in the R&D, production, and marketing of innovative medical devices in the field of electrophysiology intervention diagnosis and ablation treatment. The Company is dedicated to providing globally competitive “diagnosis and ablation treatment integrated solutions with precision intervention navigation as the core”. Since its inception, MicroPort EP has been committed to continuous innovations and breakthroughs in core technologies. Based on these core technologies, the Company has systematically deployed products and expanded their applications. Over a decade of innovation, the Company has established a comprehensive presence in the field of cardiac electrophysiology. It is the first domestic manufacturer to offer complete solutions for three-dimensional cardiac electrophysiology equipment and consumables. On August 31, 2022, MicroPort EP (688351.SH) was successfully listed on the STAR Market of the Shanghai Stock Exchange.

Founded in 1993, Hanyi Innovative Technology Co., Ltd. (also known as “Hanyi Fonts”) was successfully listed on the A-share Growth Enterprise Market in August 2022 (stock code: 301270). As a cultural and creative high-tech enterprise, Hanyi Fonts specializes in glyph design, font product development, Chinese character information technology research, and Chinese character application solutions, boasting crucial proprietary intellectual property rights.

With a top-notch professional design team, Hanyi Fonts has developed thousands of font products for B-end enterprises and C-end users. The classic fonts that the Company designed during its early stages, such as the HY Dimond Heart Font, HY Elegant English Font, HY Central Black Font, and HY Refined Line Font, have remained highly popular among the public for more than two decades. In recent years, Hanyi Banner Black, with its rigorous design language, full spectrum of fonts, and outstanding visual performance, has been widely used in various fields of graphic design and architecture, becoming a representative work in the Chinese font industry. 

Hanyi Fonts not only stays attuned to the evolving trends in humanities, quality, and popular culture, but also actively supports the cultivation of young font enthusiasts. This dedication has resulted in the creation of a continuous stream of immensely popular fonts, including the HY Mellow and Round, HY Elegant and Cool Black, and HY Small Wheat Font. These fonts have gained widespread usage in the market promotion of various Internet products. Moreover, leveraging its exceptional professional capabilities, Hanyi Fonts has successfully developed numerous customized brand fonts for diverse industries, including Huawei’s “HarmonyOS Sans”, Xiaomi’s “MiSans”, Alibaba’s “Alibaba Universal Font”, Ping An Bank’s “Ping An Warm Orange Font”, IM Motor’s “IMSans”, Game for Peace’s “Tencent Game for Peace Font”, and Amore Pacific’s “Alida Black Font.”

Advanced Micro-Fabrication Equipment Inc. China (AMEC, stock code: 688012) is a global micro-fabrication equipment company based in China. The Company provides highly competitive high-end equipment and high-quality services to the IC and pan-semiconductor industries.

The plasma etching equipment and chemical film equipment developed by AMEC are essential equipment for manufacturing microdevices, capable of processing devices at the micro and nano levels. These microdevices are the foundation of the modern digital industry and are changing the way humans produce and live. 

Headquartered in Shanghai and focusing on Asia, AMEC is dedicated to providing technical and equipment solutions to customers worldwide. As manufacturing and innovation hubs, China and Asia possess unique advantages and rapidly expanding markets, offering AMEC unlimited growth potential. 

Driven by a passion for innovation, teamwork, and mutually beneficial collaborations, AMEC has emerged as a rapidly growing microfabrication equipment company. The Company has made significant breakthroughs in technological innovation, product optimization, and market access, gaining the trust and support of numerous customers and suppliers. As a result, AMEC has become a rising star in the global semiconductor microfabrication equipment industry, boasting remarkable competitive strengths.

RemeGen Biopharmaceuticals (Yantai) Co., Ltd. was jointly founded in 2008 by Yantai RemeGen Pharmaceuticals Co., Ltd. (led by Mr. Wang Weidong) and Dr. Fang Jianmin, a scientist who had received education in the US. The Company is headquartered in Yantai, Shandong Province, China, with research institutions and offices in both China and the US. RemeGen is dedicated to the discovery, development, production, and commercialization of innovative and best-in-class biopharmaceuticals with significant clinical value in major disease areas such as autoimmune, oncology, and ophthalmology.

Established in December 1997 with a registered capital of RMB 200 million, Xingtong Shipping Co., Ltd. specializes in the water transportation of bulk liquid dangerous goods along the Chinese coast. On March 24, 2022, the Company was successfully listed on the Shanghai Stock Exchange with the stock code 603209. Xingtong holds the vice chairmanship of the Chemical Transportation Professional Committee of the China Shipowners’ Association, the vice presidency of the Dangerous Goods Logistics Branch of the China Federation of Logistics and Purchasing, the executive directorship of the China Petroleum Circulation Association, the vice presidency of the Fujian Shipowners’ Association, and the presidency of the Quanzhou Shipowners’ Association. Moreover, Xingtong is one of the three largest shipping companies in Fujian Province.

Xingtong is dedicated to becoming a world-class, nationally leading comprehensive service provider for chemical supply chains. With a strategic development plan known as “1+2+1”, the Company maintains a strong focus on its core business while continuously enhancing quality and reducing costs. Xingtong aims to expand its domestic coastal liquid dangerous goods transportation business, with a particular emphasis on clean energy transportation and international shipping. Additionally, the Company is actively developing digital platforms to support its growth and facilitate its transformation into a comprehensive service provider for chemical supply chains. These initiatives are expected to propel Xingtong towards new heights of success.

Founded in 2000, Light Electronics Co., Ltd. is the parent company of Guangdong Deep Light Technology Co., Ltd., a wholly-owned subsidiary. The Company is dedicated to the packaging of semiconductor products, infrared sensing modules, and high-quality LEDs. Over two decades of development, Light has established the most advanced LED and semiconductor packaging production lines in the industry. Moreover, the Company has fully implemented systems such as ISO9001:2008, ISO14001:2004, PB-Free, RoHS, ERP, and MES. By strictly adhering to high-end industry standards, Light meets customers’ requirements for high-quality products.

As a national high-tech enterprise, Light boasts strong R&D capabilities and a complete range of testing equipment and systems. This enables the Company to provide its customers with high-quality semiconductor packaging and testing products, as well as customized solutions for infrared sensing modules and high-quality LEDs. In addition, with a robust quality assurance system in place, Light actively engages in industry-academia collaboration, driving continuous advancements in semiconductor packaging and testing products, as well as infrared sensing module products. Moreover, Light has established semiconductor testing laboratories and assembled teams of industry-leading professionals, including top-notch overseas-educated experts. Over the years, Light has achieved remarkable outcomes in semiconductor packaging and testing, infrared sensing module applications, and peripheral supporting devices. The Company has also obtained over 30 invention patents and 40 utility model patents, with several more currently under application.

Founded in January 1997, Beijing Kaide Quartz Co., Ltd. is situated in the Industrial Development Zone of Huoxian Township, Tongzhou District, Beijing. The Company specializes in the R&D, production, and marketing of quartz glass products, such as quartz instruments, quartz pipelines, and quartz boats. As production consumables for downstream enterprises, Kaide’s products are widely used in the industries of semiconductor and IC chips and photovoltaic solar energy. For many years, the Company has engaged in the export processing of quartz glass products for 4-inch, 6-inch, 8-inch, and 12-inch semiconductor chip production lines. Its products are primarily distributed to Germany, the US, and Chinese Taiwan, encompassing hundreds of product categories. Kaide maintains a high industry standard in terms of processing technology and product quality.

Founded in March 2010, Asieris Pharmaceuticals (stock code: 688176.SH) is a global innovative pharmaceutical company specializing in the field of urogenital system tumors and other major diseases. Driven by the mission of “improving human health and helping people live a more dignified life”, Asieris aspires to become a globally leading pharmaceutical company that integrates R&D, production, and commercialization in the field of focused treatment, providing the best integrated solutions for diagnosis and treatment for patients in China and beyond. 

Empowered by innovative technologies and products, Asieris actively explores the mechanisms of drug action and efficiently screens and evaluates candidate drugs by developing proprietary R&D platforms and core technologies. With a robust internal R&D system and a wealth of experience in global drug development, Asieris is committed to advancing the field of focused treatment. The Company has successfully introduced globally first-in-class drugs as well as other innovative treatments that address critical unmet medical needs.

Furthermore, through indigenous R&D and strategic collaboration, Asieris focuses on the deep layout of product pipelines in the field of urogenital system diseases. The Company closely tracks cutting-edge technological advancements and treatment trends in this field, identifying and addressing unmet clinical needs through forward-looking product planning and lifecycle management. These initiatives have enabled Asieris to establish a strong product portfolio, spanning from disease diagnosis to treatment, ultimately benefiting a larger population of Chinese and global patients.

We are a global biopharmaceutical company in the midst of commercialization, dedicated to saving lives and improving global health through innovative vaccines.

Our mission is to bring innovative vaccines to the world, benefiting a larger population through revolutionary science and global partnerships.

Zylox-Tonbridge Medical Technology Co., Ltd. (stock code: 02190.HK) is dedicated to the innovation, R&D, manufacturing, and marketing of medical devices in the field of peripheral and neurovascular intervention and implantation. Currently, the Company owns two major brands, “Zylox Medical” and “Tonbridge Medical”, which are focused on peripheral vascular intervention and neurovascular intervention businesses respectively. The Company also engages in vascular closure business and actively develops technical and processing platforms related to medical technology.

Founded in 2007, Beijing Chemclin Biotechnology Co., Ltd. stands as one of the pioneering companies in China dedicated to the development of clinical immunology diagnostic products. The Company specializes in the R&D, production, marketing, and services of in vitro diagnostics (IVD) products.

In September 2019, Beijing Chemclin Biotechnology Co., Ltd. was restructured into Chemclin Diagnostics Corporation.

Chemclin-Boyang Diagnostics (Shanghai) Co., Ltd., located in Shanghai’s Zhangjiang Science and Technology City, is a wholly-owned subsidiary of Chemclin Diagnostics Corporation.

Founded in 2006, Ropeok Technology Group Co., Ltd. boasts extensive experience in the research of core technologies such as computer vision, semantic analysis, element perception, edge computing, data mining, deep learning, and logical reasoning. With the mission of enabling machines to “see, hear, think, and make decisions”, Ropeok is dedicated to the R&D of AI products and practical applications in various industries. With a focus on security, Ropeok serves national security strategies. Deeply rooted in industries, the Company caters to diverse sectors such as cities, transportation, industry, medical care, education, and lifestyles. By empowering industry development with AI, Ropeok strives to create a better future through technological innovation. 

Jiangsu HOB Biopharmaceuticals Co., Ltd. is a high-tech enterprise founded by nationally recognized leading professionals and returned overseas 

scholars. The Company specializes in the R&D and production of diagnostic reagents for allergies and autoimmune diseases in the field of in vitro diagnostics. HOB is dedicated to providing affordable and dependable testing products for patients.

Since its establishment in 2009, HOB has focused on the field of allergy and autoimmune disease diagnostics. Through continuous investment and robust development, HOB has transformed into a modern high-tech enterprise that integrates innovation, R&D, large-scale production, quality control, and marketing. Leveraging its core technologies, HOB has effectively met the demands of the domestic market, offering a broad range of products to satisfy diverse testing needs. The Company has emerged as a leader in allergen testing and a rising star in autoimmune disease diagnostics in China.

Shenzhen APT Medical Devices Co., Ltd. is a high-tech enterprise specializing in the R&D, manufacturing, and marketing of cardiac electrophysiology and interventional medical devices. The Company has established a strong presence in the fields of complete coronary pathway and cardiac electrophysiology medical devices, with a focus on peripheral vascular and neurovascular interventional medical devices. On January 7, 2021, the Company was successfully listed on the STAR Market of the Shanghai Stock Exchange with the stock name “APT Medical” and the stock code 688617.

Founded in September 2014, CNGR Advanced Materials Co., Ltd. (300919.SZ) is a majority-owned subsidiary and the main listed entity of Hunan CNGR Holdings Group Co., Ltd. The Company is a professional comprehensive service provider of new energy and materials in the nation’s strategic emerging industries. CNGR has been recognized as a National Enterprise Technology Center, a National High-tech Enterprise, and a National Tech Innovation Demonstration Enterprise. Additionally, the Company has received prestigious titles such as “National Intelligent Manufacturing Factory”, “Green Manufacturing Factory”, and “Green Design Demonstration Enterprise”.

Founded in October 2007, Shanghai Titan Technology Co., Ltd. (Stock Code: 688133), specializes in providing one-stop laboratory products and supporting services for scientific research and quality control personnel. The Company is committed to becoming a leading innovator in the field of scientific services, thereby playing a greater role in serving national strategies, safeguarding national research material security, and facilitating enterprise innovation and upgrading. Titan offers a broad range of comprehensive services through indigenous R&D, brand operations, brand agency, and integrated package services. These services are tailored to meet the specific needs of laboratories in diverse fields such as biomedicine, new materials, new energy, chemical engineering, fine chemicals, food and daily chemicals, as well as analysis and testing. Titan offers competitive “one-stop” products and services that cover all stages of clients’ R&D preparation, process, post-development, and production quality control. Focusing on client needs, the Company has developed eight major product lines, including high-end reagents, general reagents, analytical reagents, specialty chemicals, security consumables, instruments, laboratory construction, and research software.

Founded in 2007, MEMSensing Microsystems (Suzhou, China) Co., Ltd. has played a leading role in establishing China’s MEMS industry chain, earning a reputation as an industry pioneer.

In August 2020, the Company debuted on the STAR Market of the Shanghai Stock Exchange with the stock code 688286, becoming the first listed firm specializing in MEMS chips. MEMSensing is one of the few companies in China with the capability to design and manufacture MEMS chips across multiple categories. With four subsidiaries, the Company is dedicated to the R&D and localization of the entire MEMS industry chain. MEMSensing has been consistently ranked among “China’s Top 10 Semiconductor MEMS Companies” and “China’s Top 10 Sensor Companies”. Additionally, the Company has received the “China IC Design Achievement Award” and other prestigious accolades. MEMSensing is at the forefront of MEMS technology innovation and production applications, aiming to become a globally leading provider of MEMS solutions.

Bloomage Biotech (688363) is a renowned biotechnology and biomaterial company empowered by synthetic biology technology. Dedicated to enhancing the quality of life and extending lifespan, the Company strives to bring healthy, beautiful, and delightful life experiences to people worldwide.

NetEase Youdao is driven by a mission to empower users to achieve “efficient learning”. Leveraging powerful AI technologies, the Company has developed a range of popular learning products and services tailored to various learning scenarios. These offerings include Youdao Dictionary, Youdao Dictionary Pen, as well as other software and hardware learning tools. In addition, NetEase Youdao operates online learning platforms that offer competency courses, as well as university-level and workplace training courses. At present, the Company has over 120 million monthly active users across its product line. In October 2019, NetEase Youdao debuted on the New York Stock Exchange with the stock code DAO, becoming the first independently listed company of NetEase Group. Zhou Feng, a native of Yixing, Jiangsu, currently serves as the Executive Vice President of NetEase and the CEO of NetEase Youdao.

Founded in 2001, Colibri Technologies is a global supplier of industrial automation equipment and integrated solutions for intelligent manufacturing. The Company is primarily engaged in the R&D, design, production, marketing, and technical services of industrial automation equipment, as well as precision components manufacturing. Its main products include automated testing equipment, automated assembly equipment, automated equipment accessories, and precision components. Since its inception, Colibri Technologies has concentrated on the cross-industry application of automation technology in the field of advanced manufacturing. With a “3+N” strategic layout, the Company’s business primarily focuses on the mobile terminal and new energy industries. 

Founded in 2000, Micro-Tech Co., Ltd. specializes in the R&D, manufacturing, and marketing of minimally invasive medical devices. Committed to “serving clinical practice with technology and innovation,” the Company provides high-quality products and services to medical institutions worldwide, enabling them to raise the standard of healthcare, reduce patient suffering, and lower medical costs.

Following two decades of innovative development, Micro-Tech has expanded from a single product line of non-vascular stents to the operations of three major technology platforms. Moreover, Micro-Tech has shifted its focus on the domestic market to a dual-wheel-drive strategy that encompasses both domestic and international markets. Today, Micro-Tech stands as a leader in the field of minimally invasive diagnosis and treatment, boasting strong research and innovation capabilities, competitive advantages in its core products, as well as a track record of robust growth.

Founded in 2004, Montage Technology is a global leader in data processing and interconnect chip design, dedicated to providing high-performance, low-power chip solutions for cloud computing and AI fields. Currently, the Company has two major product lines: interconnect chips and Jintide® server platforms.

In July 2019, Montage Technology was successfully listed on the Shanghai Stock Exchange with the stock code 688008, becoming one of the first companies to list on the STAR Market. Headquartered in Shanghai, the Company has branch offices in Kunshan, Beijing, Xi’an, Macau, the US, South Korea, and other locations.

Pharmaron (300759.SZ/3759.HK) is a globally leading life science R&D service company. Since its establishment in 2004, Pharmaron has dedicated itself to fostering talent and establishing state-of-the-art facilities, resulting in the creation of a comprehensive R&D and production service system that covers the entire spectrum of drug discovery, preclinical and clinical development for a diverse range of therapeutic drugs, including small molecules, large molecules, and cell and gene therapies. With operations in China, the US, and the UK, Pharmaron boasts a global workforce of over 14,000 employees. The Company provides R&D solutions to partners in North America, Europe, Japan, and China, while maintaining strong collaborative relationships with them.

CATL is a globally leading innovative technology company in the field of new energy, dedicated to providing first-class solutions and services for global new energy applications.

Mango TV is a leading new media platform that focuses on interactive audiovisual content. It seamlessly combines the unique features of the Internet and television, offering a comprehensive and immersive audiovisual experience. As the sole internet video platform under Hunan Broadcasting System, Mango TV provides a wide range of exclusive, cross-platform, and self-produced content. In 2017, Mango TV reversed its financial situation, becoming a profitable player in the Chinese video industry with a profit of RMB 489 million. In June 2018, Happi Go (300413.SZ) obtained regulatory approvals for a major asset restructuring. As part of Hunan Broadcasting System’s “dual-core driving” strategy, Mango TV, alongside Mango Fun, EE Media, Mango Studios, and Mango Entertainment, was integrated into Happi Go in its entirety. This restructuring turned Mango TV into China’s first listed A-share video platform with state-owned controlling shares. In July of the same year, Happi Go officially rebranded itself as Mango Excellent Media.